MRNA technology takes on Hard-to-Treat multiple myeloma
NCT ID NCT07362732
First seen Jan 24, 2026 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This early-phase trial tests a new mRNA-based drug called WGb-0302 in 20 adults with recurrent or treatment-resistant multiple myeloma and other blood cancers. The therapy uses lipid nanoparticles to deliver mRNA that targets BCMA, a protein on cancer cells. The main goals are to check safety and find the right dose, not yet to prove it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
WGb-0302 injection (mRNA therapy targeting BCMA, delivered via lipid nanoparticles)
What this could lead to
If it works, this could point toward a new treatment option for patients with hard-to-treat multiple myeloma who have run out of standard therapies.
What could go wrong
This is a very early, small safety study (20 people) with no guarantee of effectiveness. The treatment may cause side effects or fail to control the cancer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.